Kornimate/medical-research-clean huggingface dataset:
impact of glycine therapy on peri-implant mucositis

Conditions: Peri-implant Mucositis

Summary: the purpose of this research study is to determine the impact of glycine powder air-abrasive debridement (gpad) on the microbiology of the tissues surrounding dental implants with health and inflammation (peri-implant mucositis).

peri-implant mucositis, or the infection of the gingival tissues surrounding a dental implant, and peri-implantitis, or the infection of the gingival tissue surrounding a dental implant with bone loss, can lead to the failure and eventual loss of dental implants. the prevalence of peri-implant mucositis ranges from 30.7-43% and the prevalence of peri-implantitis ranges from 9.6-22% with non-smokers. traditional treatment of this disease has been through biofilm removal using ultrasonic instrumentation. glycine is a non-essential amino acid that possesses an anti-inflammatory, immunomodulary, and a cytoprotective effect. the goal of this investigation is to examine the impact of glycine-augmented biofilm removal on resolution of peri-implant mucositis

Eligibility criteria:
inclusion criteria: * age \> 18 years * must have \>1 tooth-borne, non-splinted single dental implant * signs of healthy dental implants (pocket probing depth \<4mm and a lack of bleeding upon probing at peri-implant site) or * signs of peri-implant mucositis (\> 4mm probing pocket depths at the dental implant site, bleeding upon probing at \>1 peri-implant site, pre-brushing plaque score of \> 1.9 (modified plaque index (mpi)), and radiographic evidence of bone loss less than 2mm). exclusion criteria: * uncontrolled medical condition (i.e. diabetes, history of smoking \<5 years) * pregnant or lactating females * untreated periodontal conditions * use of antibiotics in the past 3 months * subjects treated with medication for \>2 weeks with known effects to the oral tissues (i.e. coumadin, phenytoin, nifedipine, cyclosporine, non-steroidal anti-inflammatory drugs) * signs of peri-implantitis (pocket probing depth of 4-6mm with bleeding upon probing at \>1 peri-implant site and radiographic bone loss) * dental implant mobility
hyperbaric oxygen in patients who had a stroke

Conditions: Stroke; Hyperbaric Oxygen

Summary: prospective clinical assessment of 40 hyperbaric oxygen (hbo) treatments in 10 completed stroke patients.

10 patients having suffered a stroke and having being rehabilitated will be treated with 40 consecutive hyperbaric oxygen treatment (hbot) after a minimal delay of 3 months after stroke. they will be neurologically assessed before and 3 months after hbot. rivermead mobility index will be also assessed.

Eligibility criteria:
inclusion criteria: * patients with ischemic cortical stroke in chronic stage (≥ 3 months) with residual motor deficits confirmed by imaging with brain ct scan and/or brain mri informed consent exclusion criteria: * neurological issue: * inability to understand the informed consent form * hemiplegia * hyperbaric issue: * claustrophobia * inability to put on face mask * uncontrolled epilepsy * dementia or psychological disturbance * previous pneumothorax * pregnancy

Keywords: hyperbaric oxygen completed stroke feasibility prospective
gts400 stent implantation in conjunction with cataract surgery in subjects with open-angle glaucoma

Conditions: Glaucoma

Summary: the purpose of this study is to evaluate the safety and efficacy of the gts400 trabecular micro-bypass stent in reducing intraocular pressure (iop) in subjects with open-angle glaucoma or ocular hypertension and co-existing cataract.

glaucoma is a collection of disorders characterized by progressive loss of visual field due to optic nerve damage. it is a leading cause of blindness in the united states, affecting 1-2% of individuals aged 60 and over. management of glaucoma requires chronic, life-long treatment with a spectrum of therapeutic options including medications, laser treatment and surgical implants. the common goal among the various therapies is to lower intraocular pressure to target levels in order to prevent loss of visual fields from excessive pressure on the optic nerve.

Eligibility criteria:
inclusion criteria: * diagnosed with open-angle glaucoma in the study eye * subject must be on 1 to 3 glaucoma medications * subject able and willing to attend follow up visits for two years postop * subject able and willing to sign informed consent exclusion criteria: * pseudoexfoliative and pigmentary glaucoma * prior glaucoma surgery of any type

Keywords: open angle glaucoma cataract surgery intraocular pressure
an interdisciplinary approach to the treatment of encopresis in children with autism spectrum disorders

Conditions: Encopresis; Autistic Disorder

Summary: the purpose of this study is to try to treat bowel movement (bm) accidents differently with children with autism spectrum disorder (asd). the study will use over-the-counter (otc) medications to evoke predictable bowel movements. this will make it possible for investigators to use certain strategies to reward bms in the toilet. independence will be increased by fading out the use of medications. the investigators will also train caregivers to implement the procedures.

a large percentage of individuals with autism spectrum disorder (asd) are delayed in achieving continence with bowel movements or never achieve it at all (i.e., they meet criteria for encopresis). this problem has tremendous ramifications for these individuals and their families because encopresis restricts them from integration with peers, limits access to educational opportunities, and carries significant social stigma. previous interventions for encopresis in this population have either been unsuccessful or required implementation over very long periods.

Eligibility criteria:
inclusion criteria: * age 5-21 * confirmed diagnosis of autistic spectrum disorder using the social communication questionnaire (scq) and the childhood autism rating scale ii (carsii) * clearance from gastroenterologist for use of glycerin suppository, bisacodyl suppository and senna * caregiver willing to give consent/assent exclusion criteria: * age under 5 year or over 21 years * does not present a diagnosis of autistic spectrum disorder * previous intestinal surgeries or concurrent enuresis * caregiver unwilling to give consent/assent

Keywords: behavioral symptoms child development disorders, pervasive bowel incontinence constipation
diagnostic performance of the candid plus pcr for the diagnosis of intra-abdominal candidiasis in critically ill patients

Conditions: Intra-Abdominal Infection; Candida; Peritonitis Infectious; Molecular Diagnostic; Critically Ill Intensive Care Unit Patients

Summary: invasive candidiasis are the most common form of fungal infection in critically ill patients, particularly intra-abdominal candidiasis (iac), which is associated with high morbidity and mortality. the current diagnostic gold standard relies on conventional fungal culture, which has a long turnaround time and may delay targeted antifungal therapy. non-culture-based assays such as 1,3-β-d-glucan lack specificity for early and definitive diagnosis. molecular diagnostics, including pcr, offer faster and more specific detection, but their clinical use remains limited. the candid plus pcr assay targets major candida species and has not yet been evaluated on peritoneal fluid. the candidiag study aims to assess the feasibility and diagnostic performance of the candid plus pcr in detecting candida spp. in peritoneal fluid from icu patients with suspected iac. this study constitutes a post-hoc analysis of the pbdg2 study (prospective evaluation of the peritoneal 1.3 beta-d-glucan for the diagnosis of intra-abdominal candidiasis in the critically ill patients) registered with the number nct 03997929). therefore, all patients have been already recruited. for the candidiag study, we will use the biological collection of peritoneal fluid issue from the pbdg2 study. all patients with confirmed intra-abdominal candidiasis are identified. we will test de candid pcr, retrospectively, on their peritoneal fluid and compared the results with the fungal culture.


Eligibility criteria:
inclusion criteria: * adult critically ill patient * with confirmed intra-abdominal candidiasis (culture positive with candida albicans, glabrata, parapsilosis, tropicalis, krusei, and dubliniensis) * enrolled in the pbdg2 study (nct 03997929) * intra-abdominal candidiasis documented at exclusion criteria: * declined to participate * intra-abdominal candidiasis caused by other candida species

Keywords: intra-abdominal candidiasis secondary peritonitis candida pcr molecular diagnostic
effect of dapagliflozin on 24-hour blood glucose in t2dm patients inadequately controlled with either metformin or insulin

Conditions: Type II Diabetes

Summary: effect of dapagliflozin on 24-hour blood glucose in type 2 diabetes patients inadequately controlled with either metformin or insulin

effect of dapagliflozin on 24-hour blood glucose in 92 type 2 diabetes patients inadequately controlled with either metformin or insulin

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (t2dm) * treated with either stable dose of metformin alone \> or = to 1500mg/day or stable dose of insulin \> or = to 30 units/day and up to 2 oad medications for at least 8 weeks * hemoglobin a1c (hba1c) 7.5% to 10.5% at screening * body mass index (bmi) \< or = to 45 kg/m2 exclusion criteria: * for patients who enter the study taking a stable dose of metformin, history of taking oad medications other than metformin during the 8 weeks prior to screening or have been on insulin therapy within 1 year of screening * for patients who enter the study taking insulin, history of taking any other therapy outside of the stable insulin and up to 2 oad medications for 8 weeks prior to screening. * use of sulfonylureas during the 8 weeks prior to screening * prior exposure to dapagliflozin or any sodium-glucose co-transporter 2 (sglt-2) inhibitor * ingestion of any medication know to affect glucose metabolism for \>7 consecutive days during the 3 months prior to screening * ingestion of prescription or over the counter weight loss medication during 3 months prior to screening
role of instructions in nitrous oxide effects and choice - 10

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. to evaluate the role of instructions in nitrous oxide subjective effects and choice.


Eligibility criteria:
please contact site for information.

Keywords: nitrous oxide instruction subjective effects reinforcer healthy volunteer
pth - preemptive treatment for herpesviridae

Conditions: Viral Pneumonia

Summary: the aim of this study is to show that a preemptive treatment by ganciclovir (for positive cmv viremia) or aciclovir (for positive hsv oro-pharyngeal pcr) is able to increase the number of ventilator-free days at day 60.


Eligibility criteria:
inclusion criteria: * mechanical ventilation \> 96 hrs and expected duration of mechanical ventilation of at least 2 days * positive blood cmv pcr (500 iu/ml) or positive oropharyngeal hsv pcr * age \> 18 years * informed consent * negative pregnancy test exclusion criteria: * \< 18 years * receiving ganciclovir or aciclovir or another antiviral agent active against hsv/cmv * had received antiviral agent active against hsv/cmv during the previous month * hypersensitivity to aciclovir/ganciclovir * pregnancy * breast feeding * bone marrow failure * solid organ recipients * bone marrow recipients * hiv positive patients * receiving immunosuppressive agents * saps ii \> 75 * withdrawing/withholding * neutropenia (\< 500 mm3) * thrombocytopenia (\< 25 g/l) * icu readmission

Keywords: cytomegalovirus herpes simplex virus icu mechanical ventilation mortality ventilator-free days pcr
biweekly actinomycin-d treatment or multi-day methotrexate protocol in low-risk gestational trophoblastic neoplasia

Conditions: Gestational Trophoblastic Tumor; Gestational Trophoblastic Neoplasia; Stage I Gestational Trophoblastic Tumor; Stage II Gestational Trophoblastic Tumor; Stage III Gestational Trophoblastic Tumor; Invasive Mole; Choriocarcinoma

Summary: the investigators conducted a randomized trial to study how well multi-day methotrexate protocol works compared to biweekly single-dose actinomycin d protocol in treating patients with low-risk gestational trophoblastic neoplasia. it is not yet known whether multi-day methotrexate protocol is as effective as biweekly single-dose actinomycin d protocol in treating patients with gestational trophoblastic neoplasia.


Eligibility criteria:
inclusion criteria: * histologically proven low-risk gestational trophoblastic neoplasia (persistent hydatidiform mole or choriocarcinoma), defined as 1 of the following: * less than 10% decrease in the beta human chorionic gonadotropin (hcg) titer over 3 weekly titers * greater than 20% sustained rise in beta hcg titer over two consecutive weeks * histologically proven choriocarcinoma * stage i - iii disease * who risk score 0-4 * no prior chemotherapy for gestational trophoblastic neoplasia * signed informed consent * performance status - gog 0-2 * laboratory examination： wbc≥3.5×10(9)/l, granulocyte count≥1.5×10(9)/l, platelet count≥80×10(9)/l, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal, bun, creatinine≤ normal。 fertile patients must use effective contraception during and for one year after study entry exclusion criteria: * histologically confirmed placental-site trophoblastic tumor (pstt) or epithelioid trophoblastic tumor (ett) * primary choriocarcinoma * who risk score \>4 * previous mtx treatment for suspected ectopic pregnancy * with severe or uncontrolled internal disease, unable to receive chemotherapy; * concurrently participating in other clinical trials * unable or unwilling to sign informed consents; * unable or unwilling to abide by protocol.

Keywords: gestational trophoblastic neoplasia actinomycin-d methotrexate low-risk
pathogen detection in hiv-infected children with non-malarial febrile illnesses using metagenomic sequencing

Conditions: HIV Infection

Summary: in uganda, 130,000 children (0-14 years of age) were living with hiv in 2018. last year, nearly 450 infants acquired hiv every day; most of them during childbirth and these are at extremely high risk of dying in the first two years of life from treatable infections which present with fever. while fevers are commonly attributed to malaria, most fevers in african children are not due to malaria and clinicians are challenged by the similar clinical features of wide spectrum of potential aetiologies. the prevalence of treatable causes of non-malarial febrile illnesses in children in africa has been reported to be 45%.

rapid diagnostic tests (rdts) for malaria have highlighted the decreasing proportion of malaria-attributable illness in endemic areas. unfortunately, once malaria is excluded, there are few accessible diagnostic tools to guide the management of severe febrile illnesses in low-resource settings. rdts for non-malarial tropical infections currently rely on detection of host antibodies against a single infectious agent yet their sensitivities and specificities are inherently limited. it should be noted that causes of non-malarial febrile illnesses (nmfis) in hiv-infected children in uganda remains scarce. there's minimal guidance on how to manage hiv-infected children with nmfis. thus, it is important that other causes of fever in african children be better characterized to facilitate optimization of diagnostic and therapeutic algorithms. considering these limitations, there is a pressing need for sensitive pathogen-detection-based approaches such as shotgun metagenomics sequencing (smgs). ultimately, in the near future, integration of whole-genome based approaches such as long-read sequencing technologies to tropical fevers is urgently needed to improve management of severe and treatable infections especially among the vulnerable groups such as hiv-infected children and adolescents presenting with nmfis. this project aims to utilise smgs to characterize microbial pathogens in hiv-infected ugandan children and adolescents admitted to baylor college of medicine children's foundation - uganda with nmfis and associated clinical presentations or comorbidities.

Eligibility criteria:
inclusion criteria: study population will include a total of 200 (100 who are \<5 years and 100 who are 6-to-14 years, including equal number of female and male study participants) hiv-infected ugandan children and adolescents admitted with non-malarial febrile illnesses (nmfis) to baylor college of medicine children's foundation - uganda. exclusion criteria: critically ill patients will not be recruited.

Keywords: shotgun metagenomics microbial pathogens non-malarial febrile illnesses
to evaluate ezetimibe plus atorvastatin versus atorvastatin in patients with high cholesterol not controlled on atorvastatin 20 mg (0653-079)(completed)

Conditions: Hypercholesterolemia

Summary: the purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.


Eligibility criteria:
inclusion criteria: * patient with ldl-c \>100 mg/dl \& on a stable dose of atorvastatin 20 mg exclusion criteria: * pregnant or lactating women or intending to become pregnant * patient with sensitivity or intolerance to ezetimibe or atorvastatin * patient with diabetes or coronary heart disease
cystic fibrosis remote monitoring system

Conditions: Cystic Fibrosis

Summary: the objective of this study is to determine if interactive technology (i.e. virtual coaching) that facilitates vest therapy goal setting and provides positive reinforcement will increase adherence to vest therapy for airway clearance in individuals with cf.

cystic fibrosis (cf) is a life-limiting multi-system disease primarily characterized by chronic lung infections and pulmonary symptoms such as cough, dyspnea, and chest tightness. those with cf rely on numerous pharmaceutical and treatment-based therapies as part of their routine care to maintain lung health. airway clearance, one such treatment-based therapy, uses breathing techniques and various vibrating devices to mobilize lung secretions and is considered a cornerstone of cf care. vest therapy, a "shaking vest" that applies pressure and high frequency vibrations to the chest wall is the most commonly used technique for airway clearance in the u.s., but adherence to recommended goals for airway clearance is low. barriers to adherence include the time limitations and unclear goal setting for effective treatment. a previous pilot study by this research team showed that cf patients find the use of airway clearance vests equipped with both pre-set and individually determined programing capabilities as well as electronic monitoring and transmitting capabilities to be acceptable and feasible. information such as vest-use time, vest pressure measures, programming choices and symptom reporting is captured by these devices and transmitted to health care teams for review as well as provided to patients to provide feedback on treatment goals. this study aims to determine if providing patients with clearly stated treatment goals and the means to monitor and receive positive reinforcing feedback on vest use through interactive technology (i.e. virtual coaching) will improve vest therapy adherence in individuals with cf.

Eligibility criteria:
inclusion criteria: * have a diagnosis of cystic fibrosis * be physically capable of and willing to use the study device * access to an internet connection * access to a mobile device capable of using applications * be familiar with how to utilize a mobile device and/or applications * self-reported cf-related therapy adherence between 25%-75% on a screening questionnaire exclusion criteria: * history of solid-organ transplant * inability to speak and read the english language * any contraindication to vest use for airway clearance
ridge preservation comparing the clinical and histologic healing of flap vs. flapless approach to grafting

Conditions: Jaw, Edentulous, Partially

Summary: ridge preservation comparing the clinical and histologic healing of flap vs. flapless approach to grafting

thirty patients will be treated using the principles of guided bone regeneration and ridge preservation. fifteen test patients will receive the flapless technique with an intrasocket cancellous cortical particulate allograft plus a facial overlay graft using a bovine xenograft plus alloderm gbr. the positive control group of fifteen patients will receive the flap technique with an intrasocket cancellous cortical particulate allograft plus a facial overlay graft using a bovine xenograft plus alloderm gbr. approximately, four months post-surgery, a trephine core will be taken from the grafted site immediately prior to implant placement and submitted for histologic processing.

Eligibility criteria:
inclusion criteria: 1. have one non-molar tooth requiring extraction that will be replaced by a dental implant. the site must be bordered by at least one tooth. 2. healthy male or female who is at least 18 years old. 3. patients must sign an informed consent approved by the university of louisville human studies committee. exclusion criteria: 1. patients with debilitating systemic diseases, or diseases that have a clinically significant effect on the periodontium. 2. presence or history of osteonecrosis of jaws. 3. patients who are currently taking iv bisphosphonates or who had iv treatment with bisphosphonates irrespective of duration. 4. patients who have been treated with oral bisphosphonates for more than three years. 5. patients with an allergy to any material or medication used in the study. 6. previous head and neck radiation therapy. 7. chemotherapy in the previous 12 months. 8. pregnant patients.